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able to tell us what is wrong with us”: a qualitative
study of patient expectations of rapid diagnostic
tests for malaria
Evelyn K Ansah1*, Joanna Reynolds2, Samson Akanpigbiam1, Christopher JM Whitty3 and Clare IR Chandler2Abstract
Background: The debate on rapid diagnostic tests (RDTs) for malaria has begun to shift from whether RDTs should
be used, to how and under what circumstances their use can be optimized. This has increased the need for a
better understanding of the complexities surrounding the role of RDTs in appropriate treatment of fever. Studies
have focused on clinician practices, but few have sought to understand patient perspectives, beyond notions of
acceptability.
Methods: This qualitative study aimed to explore patient and caregiver perceptions and experiences of RDTs
following a trial to assess the introduction of the tests into routine clinical care at four health facilities in one district
in Ghana. Six focus group discussions and one in-depth interview were carried out with those who had received an
RDT with a negative test result.
Results: Patients had high expectations of RDTs. They welcomed the tests as aiding clinical diagnoses and as tools
that could communicate their problem better than they could, verbally. However, respondents also believed the
tests could identify any cause of illness, beyond malaria. Experiences of patients suggested that RDTs were adopted
into an existing system where patients are both physically and intellectually removed from diagnostic processes
and where clinicians retain authority that supersedes tests and their results. In this situation, patients did not feel
able to articulate a demand for test-driven diagnosis.
Conclusions: Improvements in communication between the health worker and patient, particularly to explain the
capabilities of the test and management of RDT negative cases, may both manage patient expectations and
promote patient demand for test-driven diagnoses.
Keywords: Rapid diagnostic tests, Diagnosis, Malaria, Patient perceptions, Expectations, Test-driven, ACT, TargetingBackground
The introduction of more effective but more expensive
artemisinin-combination therapy (ACT) for malaria has
been accompanied by continued mis- and over-diagnosis
of malaria, and over-prescription of ACT. Reflecting ef-
forts to maximize the cost-effectiveness of ACT, reduce
the chance of resistance, and increase the number of
non-malarial febrile illness cases correctly treated, the* Correspondence: Ansahekdr@yahoo.co.uk
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DD1, Dodowa, Ghana
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reproduction in any medium, provided the orWorld Health Organization (WHO) now recommends
prompt parasitological confirmation by rapid diagnostic
tests (RDTs) or microscopy for all patients suspected
of malaria before treatment is started [1]. The scale-up
of RDTs has been rapid [2] but the use of tests has not
always translated into rational use of anti-malarials as
a considerable proportion of test-negative patients
have been found to receive anti-malarials in some set-
tings [3-10].
Though the introduction of RDTs may result in in-
creased access to parasitological testing for malaria, par-
ticularly in low-resource settings where availability andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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logical potential and cost-effectiveness of RDTs are
compromised if providers do not always follow test re-
sults in their prescribing behaviour [11]. Studies of RDT
introduction have involved various deliberate or inciden-
tal interventions, commonly training and supervision of
health workers. These studies have shown mixed results,
with some showing a significant decrease in prescription
of ACT following a negative test result (see for example
[12-14])and others showing continuing high levels of
over-prescription of ACT (see for example [4,7,8]). Dif-
ferent levels of adherence to results has in part been at-
tributed to the need for closer alignment of supporting
interventions with health worker needs in the context of
local cultures of clinical care [12,15-17]. All consulta-
tions are, however, a complex interaction between pa-
tient and clinician, and the influence of the patient on a
clinician’s practice has been recognised [18,19]. This
suggests a need to look beyond the providers and to
consider the role patients may play in the appropriate
diagnosis and treatment of malaria.
There is limited literature examining patients’ percep-
tions of RDTs. In general, these studies have explored
the ‘acceptability’ of the use of RDTs to communities, in-
cluding patients and caregivers of children [20-25], often
reporting high levels of acceptability and positive per-
ceptions of RDTs. However, it is important to under-
stand not only whether tests are acceptable or not to
those receiving them, but also how the tests are experi-
enced by patients in practice; studying the technology
in action, from the patient’s perspective [26]. This can
help to identify the network of relations and practices
that may shape how a RDT is interpreted and under-
stood by patients, providing an opportunity to explore
mechanisms through which the role of the patient may
influence the process of diagnosis and treatment for
malaria and following a negative test result. To this aim,
a qualitative study was conducted to explore the experi-
ences with RDTs of patients and caregivers who had re-
ceived a negative test result within the context of a
randomized controlled trial in public health facilities in
Ghana [8].
Methods
Study context
The study was carried out in the Dangme West District
in southern Ghana, a purely rural district with an esti-
mated 2009 mid-year population of about 142,633. The
population lives in scattered small communities of less
than 2,000 people. The district is divided into four ad-
ministrative subdistricts. There are a total of 17 health
facilities serving the population. These include four
health centres and six community-based clinics. Private
sector facilities include three private clinics and twoprivate maternity homes. There is one publicly owned
laboratory in one large health centre at Dodowa and two
privately owned laboratories in two other subdistricts.
There is also a mission clinic as well as a quasi-
government clinic. The doctor: population ratio at the
time of the study was 1: 23,722. The district had no hos-
pital at the time of the study. One of the health centres
was in the process of being upgraded to a district hos-
pital status at the time of the study.
Malaria accounted for about 50% of all reported cases
at the outpatients department in all health facilities and
most of these cases were as a result of presumptive diag-
nosis without parasitological confirmation. In the health
centre where laboratory facilities did exist, on average,
68% of malaria diagnosis was confirmed by a laboratory
test at the time of the study.
At the time of the study, there had been a policy
change from chloroquine as a first line antimalarial to
artesunate amodiaquine. However, some non-literate
community members still tended to call any antimalarial
“chloroquine”. The antimalarials prescribed for patients
diagnosed with malaria were artesunate amodiaquine or
artemether lumefantrine, the latter being the alternate
first line antimalarial. Chloroquine was no longer being
dispensed at health facilities at the time of the study and
the trial documented all drug prescriptions in the pa-
tients’ folders.
Study design
This study formed one part of a qualitative evaluation
of a randomized controlled trial to test the impact
of RDTs on prescription of anti-malarials in health
facilities with microscopy or presumptive treatment
as standard care [27]. The quantitative results of
the trial indicated that the introduction of RDTs in fa-
cilities with existing microscopy had little impact on
prescribing behaviour, but in facilities previously only
using presumptive treatment there was a significant re-
duction in over-prescription of anti-malarials. The
other part of the qualitative evaluation of this trial ex-
plored clinicians’ experiences with using RDTs in the
trial [16]. The findings indicated that meanings of RDTs
were constructed variously by clinicians through inter-
actions with colleagues and patients, and through dif-
ferent forms of participation with the tests themselves,
resulting in changed practice for some clinicians but re-
inforcing existing practice in others.
This qualitative study was undertaken at four of the
health facilities included in the trial in Dangme West
District, of which, one, health facility C, had facilities for
microscopy and three primarily practised presumptive
malaria diagnosis and treatment. The health facilities in
the study varied in size and composition: health facility
C was a large health centre with a high patient load
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provided curative care, supported by 10 nurses. Health
facilities A and B were smaller. One was a small health
centre (B) whilst the other was a community clinic (A).
Both had five prescribers, including one medical assist-
ant at the health centre. Health facility D was a private
clinic with one medical assistant prescribing.
Patients who had recently been tested with an RDT
with a negative test result in the study health facilities
were eligible for participation in focus group discussions
(FGDs), as were mothers of children less than five years
of age whose children had tested negative with an RDT.
Recruiting only those who had received a negative test
result reflected interest in the practice of over prescrip-
tion of anti-malarials for patients without a confirmed
malaria diagnosis. To explore this in more depth, the
sample was stratified by two subcategories: 1) those who
had been prescribed anti-malarials following their nega-
tive test, and 2) those who had not been prescribed anti-
malarials. FGDs were also segregated by gender to allow
for more open discussion (see Table 1 for a breakdown
of the FGDs by subgroup). Two FGDs were planned for
patients recruited to the trial at each of the larger health
facilities (A and C); only one FGD was planned to repre-
sent each of the smaller facilities where recruitment was
slower and could have affected recall for patients en-
rolled a long time before the FGD.
Sampling for the FGDs was systematic. After seeking
permission from community leaders to conduct the
FGDs, potential respondents who represented the sub-
groups of interest were identified from the records of
the main trial about six weeks after the trial ended.
Those recruited into the trial most recently were invited
first to participate, and further participants were identi-
fied and invited by working backwards in time through
the trial database. No more than five people were se-
lected from any one day of the trial, in order to reflect a
variety of clinician and day circumstances at any one fa-
cility. Twelve community members were invited for each
focus group. If any declined at the time of invitation, the
plan was to note them in the study log and select further
people using the same selection procedure. However,
none of the respondents invited to participate declined
to do so.Table 1 Description of selection criteria of clients participatin
Focus Group 1 2
Number of FGD participants 9 8
Health facility A A
Patient type Female Male
RDT result Negative Negative
Anti-malarial (AM) prescribed or not AM prescribed AM prescribed NoConducting focus group discussions
FGDs with community members were conducted within
the communities in which the health facilities were lo-
cated, and guidance was sought by community leaders
as to the most appropriate time and place to hold the
discussions. Each potential respondent was contacted by
the study team by phone or face-to-face visit to invite
them to the group discussion. FGDs were conducted be-
tween 20 March and 8 April, 2009.
After giving information about the study and gaining
consent from respondents, FGDs were conducted in the
local language. Confidentiality and anonymity were as-
sured, ground rules were discussed with each group and
permission was sought to record the discussions. A
semi-structured topic guide was followed, focusing on
perceptions of malaria risk and symptoms, perceptions
of and experiences with RDTs, trust in test results, per-
ceptions of treatment, and interaction with clinicians.
No incentive was provided, other than refreshments and
reasonable transportation costs.
In addition to the audio recordings, demographic data
were collected from respondents and notes of the dis-
cussion were taken by a note-taker to capture non-
verbal communication, and information about the set-
ting and atmosphere. Immediately after each FGD, a
contact summary form was completed to capture the
discussion content and atmosphere, identify any emer-
ging themes and make any suggestions for revisions to
the topic guide. All respondents’ remained anonymous
after the discussion using pre-assigned identification
numbers.
Data analysis
Audio files were transcribed phonetically in the original
language (Dangme or Ga) and then translated into Eng-
lish. Sections of text were double-checked for accuracy
of translation by other members of the field team. Tran-
scripts were then imported into QSR Nvivo 9. Coding
took place through an iterative process. Coding was
done line by line to generate a ‘node tree’ describing the
contents of the data across each transcript. Each tran-
script was then revisited to re-allocate text to new codes
where appropriate. The nodes were then grouped into
categories to generate cross-cutting themes. Theseg in the FGDs
3 4 5 6
9 10 8 Plus 1 IDI 9
B C C D
Female Male Mothers Mother
Negative Negative Negative Negative
AM prescribed No AM prescribed AM prescribed No AM prescribed
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subgroups of the respondents, by the categories “negative,
received an anti-malarial” and “negative, received no anti-
malarial” to see if the themes applied to different groups.
The themes that emerged from the data were also consid-
ered in the light of the initial conceptual framework to
generate findings.
Ethics
The ethical review boards of Ghana Health Service and
the London School of Hygiene & Tropical Medicine
approved the study. The trial which preceded this
study was prospectively registered at ClinicalTrials.
govNCT00493922.
Results
Respondents
The total number of FGDs conducted was six, with an
average of nine respondents in each, and 53 respondents
in total (see Table 1). An additional in-depth, one-on
-one interview was conducted with a mother from
health centre C who arrived late for the FGD and re-
quested to participate. She did not attend the FGD and
as such was unaware of the responses the group mem-
bers had given earlier. The transcript from this interview
was coded alongside the corresponding FGD from the
same facility.
Overview of results
Respondents had high expectations of RDTs. They per-
ceived a valuable role for RDTs as part of a process to
help the clinician reach the right diagnosis and treat-
ment decision. RDTs were also described as useful for
communicating their problem to the clinician. However,
narratives of the experience of being tested portrayed
conceptualizations of the RDT as a generic test able to
identify any cause of illness, not just malaria, and expec-
tations that a test should result in a diagnosis, even fol-
lowing a negative result. Respondents also identified a
limited effort by clinicians to engage patients in the
process by which their illness was diagnosed and treat-
ment prescribed. Clinicians appeared to retain strong
hierarchical distinctions, played out in dismissive atti-
tudes and lack of communication. As such, the tests
appeared to have been adopted into an existing opaque
system, with hidden processes of tests and silent pro-
cesses of diagnostic and treatment decisions.
Although there was a small amount of variation in re-
sponses within and across focus groups, this did not
seem to be related to the different subgroups of respon-
dents (males, females and caregivers) or to whether or
not they had received an anti-malarial following their
negative test result. In the discussions with caregivers
(mothers), many respondents talked about their personalexperiences of being tested, as well as experiences of
their children, and often the two were not easily distin-
guishable. The themes and constructs presented below
were represented in the different sub-groups and FGDs
(except where otherwise indicated), and the quotations
have been selected to be illustrative of these key themes,
rather than reflect each FGD.
Understandings of malaria
To contextualize the findings, it is important to present
respondents’ understandings of malaria and its symp-
toms. In most discussions, malarial illness was attributed
to a range of factors, including the weather, poor hy-
giene, working hard and mosquitoes. These do not dir-
ectly relate to the concept of malaria parasites being the
direct, and only, cause of ‘true’ malarial disease. Respon-
dents were very familiar with biomedical signs and
symptoms of malaria, such as fever, body pain and weak-
ness. Some signs and symptoms of complicated malaria
were described in detail:
“Sometimes you can begin to see things and you can
leave the house and go to places you are not conscious
of ”. (Respondent 04; FGD4)
In general, many respondents perceived malaria to be
a “bad illness”.
“Malaria is a bad illness. It is capable of rendering the
body weak. It can reduce your strength or affect your
level of intelligence. That is how I see it”. (Respondent
06; FGD 2)“When the child has high temperature and you keep
the child in the house, his condition would worsen and
you would realize that the child will become very
weak. His eyes also changes and if you don’t rush the
child to the clinic it can kill him”. (Respondent 02;
FGD 6)
Finding a cure: high expectations of rapid diagnostic tests
RDTs improve clinical decisions
When asked about their experiences with the ‘new test’,
and/or the ‘RDT test for malaria, respondents described
the test as a valuable addition to the clinician’s process
of diagnosis and treatment of their illness,
“Doctors are not soothsayers who can just look at your
face know what is wrong with you. He has to test you”.
(Respondent 06; FGD 2)
RDTs were seen as contributing to the clinician’s diag-
nostic and treatment decision by revealing the cause of
illness present in the patient’s blood,
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cause of the illness; that is why you are asked to go
for the test. That is what I think”. (Respondent 05;
FGD 3)
The tests were seen to enable the clinician to make an
accurate diagnosis that would lead to the prescription of
the ‘right’ treatment, which would “cure the disease” (Re-
spondent 06; FGD 4). A number of respondents indi-
cated that the treatment prescribed following a test
would be more effective than drugs taken without test-
ing, resulting in a quicker recovery and removing the
need to seek care multiple times for the same illness:
“When you are tested, the problem is solved once”.
(Respondent 06; FGD 6)
“It is the test that can help us. If we don’t do the test
and the Doctor gives us drugs, the sickness may not
stop because it may be due to other ailments and not
malaria alone. That is why the test is required”.
(Respondent 01, FGD 4)
The test can identify any cause of sickness
Respondents went beyond the idea that RDTs were able
to detect malaria specifically, which was described by
some, to convey an understanding that the test could
detect in the blood any cause of illness. As such, the test
was perceived as important for enabling the doctor to
“properly diagnose the disease” (Respondent 03, FGD 5)
whatever that may be. Consequently, the respondents
expected that if the test produced a negative result for
malaria, it should reveal an alternative cause for their
illness, to guide the clinician’s prescription of treatment:
“Even if the test result is negative, they [the clinician]
should be able to tell us what is wrong with us or tell
you that it is not malaria but rather this sickness and
prescribe drugs for us”. (Respondent 05; FGD 1)
Respondent stories showed how the RDT was seen as
a central activity in finding the cause of the illness.
“When you are tested, they can diagnose the cause of
your illness”. (Respondent 03; FGD 2)“I think because you don’t know what the cause of
your illness is, that is why they ask you to go for the
test so that they will know what the cause is and give
you medication. This is my view” (Respondent 03;
FGD 3)
The test was thought to be able to tell at what stage
the malaria was, in order to prescribe the appropriatedose of medication to deal with it as indicated in this ex-
ample below:
“Even if the doctor knows you have malaria he would
like to conduct the test to determine the stage of the
disease so that he can give you the right dose of the
drugs that can cure the illness”. (Respondent 09; FGD 5)
The test can communicate the problem to the doctor
Several discussions suggested the test was perceived to
play an important role in communicating on behalf of the
patient to the clinician. Respondents explained that some-
times they and patients in general, were unable to express
themselves well or explain their symptoms clearly to the
clinician. The test provided a means for clinicians to get
around this gap in communication, as it was perceived to
convey better their signs of illness:
“Sometimes we don’t explain ourselves well to the
doctors, so they will ask us to go for the test to be sure
of what the problem is before they give us drugs”.
(Respondent 04; FGD 4)
These perceptions of the inadequacy of patients’ com-
munication of symptoms, in comparison with the test,
were framed by broader descriptions of the challenges of
interacting with clinicians. These arose from more gen-
eralized statements about experiences of clinicians’ nega-
tive attitudes towards patients, not necessarily linked to
their experiences of testing:
“Sometimes when you start discussing your problem,
then they begin to shout at you. The next time you go to
the clinic, you will find it difficult to tell them the truth
or discuss your problem with them because of what
happened the previous visit”. (Respondent 01; FGD 6)
Thus, one of the ways that RDT enabled the right diagno-
sis and treatment for a patient was through communicating
their problem in a way that was acceptable to clinicians.
Although other research on RDTs has indicated that
some people confuse the malaria test with tests for HIV,
and fear the possibility of it revealing a positive HIV sta-
tus (for example see [21]), only one respondent in this
study articulated a question of whether the RDT could
detect HIV. Rather, the RDT was widely conceived as an
all-purpose means by which clinicians would be able to
identify the cause of illness.
Hidden processes and silent diagnoses: limited patient
engagement
Testing as a hidden process
When asked to describe their experiences with proce-
dures of testing with RDTs, respondent accounts lacked
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focused on experiences of having blood taken and
waiting time.
“They took my blood and asked me to wait. When he
brought the result he said he did not find anything in
the blood and I was told to go”. (Respondent 04;
FGD 2)
Comparisons were made with microscopy in this re-
gard. Some thought the quantity of blood taken for the
new test was less than for microscopy, and as a result
the test was less painful which was preferable. In
addition, many respondents were positive about the
RDT taking less time than microscopy at the laboratory,
and reported not minding waiting for the RDT result to
be produced. Several respondents suggested that this
waiting time was an important feature of the process
through which the clinician would determine the cause
of illness via use of the test:
“Because your aim is to get well the time is not an
issue. You don’t know what the doctor has seen that he
has asked you to go for the test. You must always
exercise patience so that the doctor can know what is
wrong with you and give you medication. If you really
want to be cured you should have patience. The time
should not be an issue”. (Respondent 01; FGD 3)
The lack of detail of the test itself may reflect the sep-
aration of patients from laboratory procedures. The trial
introduction of RDTs followed standard practice in
Ghana to perform tests in a laboratory or special room,
separate from patients and from the consulting room,
and to return the results to the clinician to interpret.
When describing testing procedures, respondents
often referred to RDTs as a “machine”, using the English
word, despite communicating in the local Ga-adangme
language. This identifies the test as a technology outside
of the local or lay domain, conceived as complex and
not clearly understood, and occurring separately from
the usual consultation with the clinician. This
conceptualization indicates a perceived mystification of
the technological process of the test, which may contrib-
ute to the expectations held by respondents of the test’s
capacity to diagnose any disease.
“I don’t understand the new test. When they take your
blood sample, which machine do they put the blood
sample in? What do they do with it?” (IDI)
Results unknown: part of a silent diagnosis
Patients gave mixed reports of whether they were told
the results of the test or not. Laboratory staff, in themain, left the communication of test results to the clini-
cians. Some patients reported not having received the
results of RDTs at all or not directly during the consult-
ation with the clinician, exemplified in this group
discussion:
“Moderator (M): Was the result of the test disclosed
to you?
07: They never told me what was wrong with me.
04: Even though the test result shows I had no
malaria, because of the way I was feeling, the Doctor
said they should give me some malaria drugs.
05: I was not told the result of the test. He [the
laboratory technician] asked me to take the result to
the nurse [clinician] and it was the nurse [clinician]
who told me I had malaria.
02: No, they asked me to see [name of nurse] and
when I went the nurse [clinician] told me.
01: No, they did not tell me anything, not even the
nurse [clinician]”. (FGD 2)
In many cases, the hidden nature of the testing process
appeared to be extended to the results themselves, incor-
porated into an opaque diagnostic process by the clinician:
“The issue is that the result of the test is stapled and
so you cannot open it. It is the Doctor who opens it
and he can decide to tell you or not”. (Respondent 06;
FGD 4)
“The lab technician told us that he will send the result
to the Doctor when he comes. He told me he does not
know the result of the test but will show it to the
Doctor when he comes”. (Respondent 06, FGD 2)
Responses of some patients suggest they interpreted a
malaria diagnosis even though, according to trial re-
cords, their RDT was negative. This could reflect a mis-
interpretation of interaction with the clinician or, for
those who were prescribed anti-malarials following a
negative test, an interpretation of receiving this prescrip-
tion as indicative that they had been given a malaria
diagnosis. It is also possible that respondents were
reflecting on different treatment seeking episodes than
the case recorded in the trial, limiting our ability to ex-
plore this theme in more detail in our data. However, if
malaria diagnoses were inferred for RDT negative cases,
this suggests further potential consequences of the silent
process of diagnosis described by respondents.
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questioned
Many respondents conveyed their unwillingness to ques-
tion or challenge the clinician’s decisions around whether
to test and how to respond to the test result.
“I am always glad when the Doctor asks me to go for
lab test because I would be wondering what is causing
my illness. Sometimes I feel like telling the Doctor I
want to go for lab test but I don’t know what is on his
mind. So when he eventually tells me to go for the test
I become happy”. (Respondent 08; FGD 3)
Descriptions of clinicians as “second gods” conveyed
perceptions of the level of authority held by them, and
this underpinned respondents’ statements about the clin-
ician alone knowing how to interpret a test and pre-
scribe the right treatment:
05: “You are talking about a situation where I am
expecting that the Doctor will give me a specific drug
but he gives me a different drug.
M: Yes
05: Doctors are our second gods. Whatever sickness
they will find in your body they will give you drugs
that will cure that disease. So I will not be bothered”.
(FGD 1)
“When you are sick and you go to the clinic and you
go for the test and the test reveals the cause of your
sickness, it is only the doctor who can find solution to
that problem. So it all depends on what the doctor
thinks is the right thing to be done”. (Respondent 04;
FGD 4)
Many respondents conveyed their role as a passive re-
cipient of care, entrusting the clinician -with the respon-
sibility to know and prescribe what was ‘right’ for them.
The enactment of this role, coupled with expectations of
clinical authority, meant clinical decisions should not be
questioned by the patient:
“We will accept any drug the Doctor will give us. He
has conducted test on us and has seen the result, so
whatever drug he will gives us we can’t say anything.
This is what I think”. (Respondent 01; FGD 3)
“We cannot say anything. We can’t tell the Doctor to
give us paracetamol, chloroquine, blood tonic or
malaria drugs. It is what we tell them and what they
will diagnose that will inform them about the kind of
drug he will give us”. (Respondent 01; FGD 1)This theme of acceptance of the clinician’s prescribed
treatment emerged alongside some respondents’ state-
ments that they were not told the results of the RDT,
and therefore, presumably, were not informed of a test-
based diagnosis of their illness. This stands in contrast
with the expressed desire and expectation by many
respondents, based on their understanding the RDT,
that they should be told the exact cause of their illness
after testing.
Situations of patient action
In contrast with the lack of involvement in testing, diag-
nostic processes and decisions, some patients felt they
could play a role in some decisions. Within the clinical
encounter, it appeared acceptable to negotiate regarding
the specific medicine prescribed once a diagnosis has
been made, for example to inform the clinician if the
drug he prescribed had caused unpleasant effects in pre-
vious experiences and to request something else:
“Chloroquine is good for some people but chloroquine
is not good for me. Even if I take four tablets, my body
will itch for about a week. What I normally do is I tell
the Doctor what chloroquine does for me and he will
either change it or add some drugs to stop the itching”.
(Respondent 08; FGD 3)
Patients also described their ability to find alternative
solution to their illness outside of the health facility en-
vironment. While they would not challenge the clini-
cian’s prescription, they would seek care elsewhere if
dissatisfied with the drug treatment or if perceiving it
not to work. Community drug stores were mentioned in
several discussions as alternative sources of care:
“If the drug doesn’t work, you can go to the drug store
and explain your condition and see if you can get
other drugs”. (Respondent 03; FGD 1)
“I went for the lab test on Friday but I bought some
drugs over the weekend from the drug store
(Maladrin). On Monday I went back to see the Doctor
with the lab result and I showed him the drug I took”.
(Respondent 01; FGD 4)
Discussion
The debate on RDTs has begun to shift from whether
RDTs should be used, to how and under what circum-
stances their use can be optimized [1]. Calls for the in-
creased availability of RDTs in both the public and
private sectors, as part of efforts to rationalize the use of
ACT [28,29] have increased demand for a better under-
standing of the complexities surrounding the role of
RDTs in appropriate treatment of fever. This qualitative
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interaction with RDTs following their introduction
to health facilities in one district in Ghana [8,16], to
explore the perceptions and experiences of patients
and caregivers of children who had been tested as part
of the trial.
In this study, patients who had been tested with RDTs
held positive, but often technically inaccurate, percep-
tions of RDTs, and considered their role in accurate
diagnosis and treatment of their illness to be valuable.
Their expectations for the RDT to identify any cause of
illness – not just malaria – could however in time com-
promise this apparent acceptability of the tests as they
become more established in the health care context if
not addressed, as it cannot be realized. Patient experi-
ences of RDTs were embedded in existing hierarchical
social relations between clinicians and patients, with pa-
tients perceiving limited ability to engage in the clinical
process and to influence providers’ behaviour around
testing and treating malaria. The finding that the tech-
nical mechanisms of RDTs were not seen to be part of
the lay domain, combined with the perception of the
diagnostic process as housed in the clinical domain, sug-
gests that patient demand for treatment to directly fol-
low test results in this setting is currently limited.
The highly positive perceptions of RDTs demonstrated
by patients in this study correspond closely with other
similar studies conducted in Ghana, Tanzania and
Uganda [20,21,23-25]. Others have also identified that
RDT acceptability is based on its perceived role in aiding
the clinician to reach a more definitive diagnosis and
prescribe the right treatment for their illness [20,23].
The value of the test in communicating a patient’s ‘prob-
lem’ to the clinician more clearly than they could ver-
bally, has also been reported elsewhere [24]. However,
beyond this, it was found that perceptions of RDTs were
underpinned by unrealistically high expectations from
the tests. Respondents in the study perceived the RDT as
able to detect any cause of illness, beyond malaria. This
may indicate interpretations of the technology as an ‘ob-
ject of hope’ in terms of curing illness [30] and may re-
flect broader ideas that the quality of health care is
equated with use of new technologies like RDTs [23],
framed by an assumption that problems are resolvable
through technological means [31].
Study respondents described the test as a ‘machine’, a
descriptor also reported for RDTs elsewhere in Ghana
[24], suggesting recognition of a highly technological
and complex process by which a result is produced. Be-
yond this, patients were unable to describe the processes
of the RDT. Rather, the position of testing in a labora-
tory or special testing room outside of the lay purview,
seemed to allocate to the test a status of mystery and
power, described for biomedical investigations elsewhere[32]. This finding contrasts with the other study of pa-
tient experiences with RDTs in Ghana where patients
were able to describe clearly the way the tests give re-
sults, in a context where the patients had attended study
clinics, run by well-trained fieldworkers as part of a clin-
ical research team [24]. It is possible that there the test
was carried out more openly by the fieldworkers, along
with explanations about the tests to patients. This may
have affected some of their perspectives of the test as a
more objective indicator of malaria than clinical opinion.
In this study, where testing was incorporated into rou-
tine services, patients presented themselves as outside of
RDT processes. Test results were elusive, and patients
did not identify mechanisms by which the test should
determine clinical management decisions. This suggests
that the tests were not seen as independent objects, but
as part of the clinical process under the expertise of the
clinician.
The goal to achieve universal parasitological diagnosis
of malaria through improved access to testing rests on
the assumption that tests, such as RDTs, provide object-
ive criteria for malaria diagnoses. As such, the tests are
held to be the locus of knowledge for making a treat-
ment decision. However, the findings of this study sug-
gest that in a routine scenario in Ghana, RDTs were
adopted into a practice where the clinician retains the
locus of knowledge, and power, for clinical decisions. Pa-
tients expected clinicians to use tests and their results
alongside clinical expertise to provide appropriate treat-
ment for their diagnosis. This suggests that RDTs did
not undermine clinicians’ position and credibility with
patients, reported as a fear of clinicians in Uganda [23],
but it also suggests that pressure from patients to use
RDTs as a primary determinant of anti-malarial usage
may be limited in contexts such as this. The finding
echoes results from Tanzania where clinician percep-
tions of patient pressure for anti-malarials were not up-
held by patient expectations for the right diagnosis and
treatment [33].
Implications
The findings presented in this study suggest that, whilst
RDTs are clearly welcomed by patients, two issues need
to be addressed from the patient perspective in order for
RDTs to achieve the potential intended by policy makers
and funders. First, expectations that RDTs are able to
diagnose any illness need to be managed in order to
lessen risks of reduced acceptability of the tests since
any mistrust of the new tests among the public will
affect their acceptability [34]. Second, and related, the
link between RDTs, their results, diagnoses and treat-
ment decisions need to be made transparent. Both can
be addressed through improved communication with pa-
tients, particularly by health workers themselves. The
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tem of opaque diagnosis, embedded in a system of clin-
ician authority and patient (blind) trust, to an open
encounter that lays bare what is known and unknown in
the process of test result-determined decisions. In the
analysis of health worker experiences of RDTs in this
same trial, respondents conveyed that investing in better
communication with patients, particularly in the face of
negative RDT results, was difficult at times but worth-
while [16]. Elsewhere, trials to evaluate the impact of the
introduction of RDTs alongside supporting interventions
that include training in improved communication are
on-going and will inform methods for undertaking such
interventions. Beyond goals to manage expectations
from RDTs and promote test-based diagnoses, improved
communication may influence patients’ and caregivers’
understandings of diagnoses and treatment regimens for
febrile illness in general, potentially affecting adherence
to treatment, perceptions of quality of care, and future
care seeking decisions [27,35,36].
Limitations
The number of FGDs (six) and one interview conducted
reflects a fairly small sample size, although no new
themes or ideas were identified in the final discussions,
suggesting that a level of saturation had been achieved.
The study was conducted in a single district, which po-
tentially limits the extent to which the results can be
considered applicable outside the specific study context.
However, many of the findings correspond with other,
similar studies elsewhere including Ghana. The period
that had elapsed between the time of visit and the FGD
in the case of some respondents may have diminished
recall to a certain extent, but this was not evident in the
discussions as respondents appeared to talk easily about
their experiences. The two groups of caregivers tended
to narrate experiences from visits during their own re-
cent illness episode as well as those of their children,
and the two were often indistinguishable. It is possible
that caregivers had themselves experienced RDTs as part
of the trial at another point in time, giving them further
insights into the test. In addition, the way testing was
discussed, often as ‘testing’ rather than using a word for
RDTs, suggests that broader experiences with testing are
likely to have been drawn upon in the reflections of re-
spondents. This has the potential to provide a more inte-
grated narrative of RDTs in context but in places it also
limited interpretations to testing in general rather than
RDTs in particular.
Direct observations of clinician-patient interactions
might have offered insight into how patients’ perceptions
of RDTs were shaped by the clinical encounter in this
context. However, we did not directly observe the inter-
actions between the clinician and the patient as ourfocus was to understand how patients and local commu-
nities made sense of these interactions when RDTs are
involved. In addition, direct observation would have had
implications for the results of the randomized controlled
trial in which this qualitative study was situated.
Conclusion
When seen as an objective tool to identify malaria cases,
RDTs have the potential to contribute to universal para-
sitological diagnosis and appropriate treatment for all
patients suspected to have malaria. When RDTs are
adopted into existing scenarios of hidden, or silent,
diagnostic processes, where clinicians retain authority
that supersedes tests and their results, patients are un-
able to demand a test-driven diagnosis and this potential
is reduced.
The positive perceptions of patients about a diagnostic
system incorporating RDTs show these tests as a wel-
come addition. However, misconceptions of the test’s
ability to detect any cause of illness sets patients up for
disappointment, particularly if the testing process be-
comes more transparent. Improvements in communica-
tion between the health worker and patient, particularly
to explain the capabilities of the test and management of
RDT negative cases, may both manage patient expecta-
tions and promote patient demand for a more test-driven
diagnosis. There is also a need for a corresponding im-
provement in the communication between laboratory
technicians and the patient so that patients can under-
stand what to expect during the testing process and why
they need to return to the clinician to discuss the results
of the test.
This may increase satisfaction with test-based diagno-
ses, reduce alternative careseeking and improve accept-
ance of and adherence to prescribed treatments.
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